HANSA MEDICAL AB ORD news, videos and press releases - Page 5
For more news please use our advanced search feature.
HANSA MEDICAL AB ORD - More news...
HANSA MEDICAL AB ORD - More news...
- Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Half of 2020 and Business Update
- Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU
- Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
- Hansa Biopharma Appoints Achim Kaufhold as CMO to Support the Expansion Outside Transplantation
- Hansa Biopharma Submits Responses to Outstanding Questions From EMA on May 26
- Notice to Annual General Meeting in Hansa Biopharma AB (publ)
- Hansa Biopharma Announces Upcoming Presentations Including a Late Breaking Poster Presentation at the 2020 American Transplant Congress
- Hansa Biopharma to Participate in Five Upcoming Investor Conferences During May and June
- Hansa Biopharma Interim Report Jan-Mar 2020. EMA Process on Track; an Opinion From the CHMP is Expected in the Second Quarter 2020
- Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Quarter of 2020 and Business Update
- Hansa Biopharma Publishes Annual Report 2019
- Hansa Biopharma Announces Long Term Follow-up Data That Demonstrates 2-year Graft Survival of 89% After Imlifdase Treatment and Transplantation
- Hansa Biopharma to Participate in Two Upcoming Investor Conferences
- Hansa Biopharma Year-End Report 2019
- Hansa Biopharma Completes Enrollment in Anti-GBM
- Hansa Biopharma to Host Conference Call to Provide Year-End report 2019 and Business Update
- Hansa Biopharma Provides Business Update Ahead of the JP Morgan Global Healthcare Conference
- Hansa Biopharma has Agreed With the FDA on a Regulatory Path Forward for Imlifidase in Kidney Transplantation of Highly Sensitized Patients in the U.S.
- Hansa Biopharma Nomination Committee Formed
- Hansa Biopharma Interim Report January-September 2019
- Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Nine Months of 2019 and Business Update
- Hansa Biopharma Confirms Follow-up Meeting With FDA
- Hansa Biopharma: Positive Results Presented at ESOT; Imlifidase Enabled Transplantation in 46 Sensitized Patients
- Hansa Biopharma: Issue and Re-purchase of Class C Shares for Incentive Programme
- Hansa Biopharma: New Imlifidase Data Presented at ESOT, Copenhagen
- Hansa Biopharma to Participate in Three Upcoming Investor Conferences
- Hansa Biopharma Interim Report January-June 2019
- Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update
- Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls
- Hansa Biopharma to Participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City
